https://www.deadiversion.usdoj.gov/21cfr/cfr/1301/1301_74.htm
Extracted by GlobalMSDS Ltd
7 January 2019
storing controlled substances in a public warehouse, a registrant is responsible for selecting a
warehouseman which will provide adequate security to guard against storage losses; wherever
possible, the registrant shall store controlled substances in a public warehouse which complies
with the requirements set forth in
. In addition, the registrant shall employ
precautions (e.g., assuring that shipping containers do not indicate that contents are controlled
substances) to guard against storage or in-transit losses.
(f) When distributing controlled substances through agents (e.g., detailmen), a registrant is
responsible for providing and requiring adequate security to guard against theft and diversion
while the substances are being stored or handled by the agent or agents.
(g) Before the initial distribution of thiafentanil, carfentanil, etorphine hydrochloride and/or
diprenorphine to any person, the registrant must verify that the person is authorized to handle
the substance(s) by contacting the Drug Enforcement Administration.
(h) The acceptance of delivery of narcotic substances by a narcotic treatment program shall be
made only by a licensed practitioner employed at the facility or other authorized individuals
designated in writing. At the time of delivery, the licensed practitioner or other authorized
individual designated in writing (excluding persons currently or previously dependent on narcotic
drugs), shall sign for the narcotics and place his specific title (if any) on any invoice. Copies of
these signed invoices shall be kept by the distributor.
(i) Narcotics dispensed or administered at a narcotic treatment program will be dispensed or
administered directly to the patient by either (1) the licensed practitioner, (2) a registered nurse
under the direction of the licensed practitioner, (3) a licensed practical nurse under the direction
of the licensed practitioner, or (4) a pharmacist under the direction of the licensed practitioner.
(j) Persons enrolled in a narcotic treatment program will be required to wait in an area
physically separated from the narcotic storage and dispensing area. This requirement will be
enforced by the program physician and employees.
(k) All narcotic treatment programs must comply with standards established by the Secretary of
Health and Human Services (after consultation with the Administration) respecting the
quantities of narcotic drugs which may be provided to persons enrolled in a narcotic treatment
program for unsupervised use.
(l) DEA may exercise discretion regarding the degree of security required in narcotic treatment
programs based on such factors as the location of a program, the number of patients enrolled in
a program and the number of physicians, staff members and security guards. Similarly, such
factors will be taken into consideration when evaluating existing security or requiring new
security at a narcotic treatment program.
(m) A reverse distributor shall not employ, as an agent or employee who has access to or
influence over controlled substances, any person who has been convicted of any felony offense
relating to controlled substances or who, at any time, had an application for registration with
the DEA denied, had a DEA registration revoked or suspended, or has surrendered a DEA
registration for cause. For purposes of this subsection, "for cause" means in lieu of, or as a
consequence of, any Federal or State administrative, civil, or criminal action resulting from an
investigation of the individual's handling of controlled substances.
[36 FR 7778, Apr. 24, 1971. Redesignated at 38 FR 26609, Sept. 24, 1973]
Editorial Note:
For Federal Register citations affecting ยง1301.74, see the List of CFR Sections
Affected, which appears in the Finding Aids section of the printed volume and at www.fdsys.gov.